Abstract

Lrig1 is the founding member of the Lrig family of transmembrane leucine-rich repeat proteins, which also includes Lrig2 and Lrig3. Lrig1 is a negative regulator of oncogenic receptor tyrosine kinases, including ErbB and Met receptors, and promotes receptor degradation. Lrig1 has recently emerged as both a tumor suppressor and a key regulator of epidermal and epithelial stem cell quiescence. Despite this, little is known of the mechanisms by which Lrig1 is regulated. Lrig3 was recently reported to increase ErbB receptor expression suggesting that it may function in a manner opposite to Lrig1. In this study, we explore the interaction between Lrig1 and Lrig3 and demonstrate that Lrig1 and Lrig3 functionally oppose one another. Lrig3 opposes Lrig1 negative regulatory activity and stabilizes ErbB receptors. Conversely, Lrig1 destabilizes Lrig3, limiting Lrig3's positive effects on receptors and identifying Lrig3 as a new target of Lrig1. These studies provide new insight into the regulation of Lrig1 and uncover a complex cross-talk between Lrig1 and Lrig3.

Highlights

  • Lrig1 is a negative regulator of oncogenic receptor tyrosine kinases

  • Lrig1 Negative Regulatory Function Is Unique among the Lrig Family—Lrig1 was first described as an ErbB negative regulator in 2004 [1, 2], and subsequent studies extended this role to the Met [4] and Ret [5] receptors

  • Lrig1 has recently emerged as an essential regulator of stem cell homeostasis with loss of Lrig1 perturbing both epidermal and epithelial stem cell dynamics [16, 17, 33]

Read more

Summary

Background

Results: Lrig opposes Lrig negative regulatory action and enhances ErbB receptor stability. Lrig is a negative regulator of oncogenic receptor tyrosine kinases, including ErbB and Met receptors, and promotes receptor degradation. Lrig was recently reported to increase ErbB receptor expression suggesting that it may function in a manner opposite to Lrig. Lrig opposes Lrig negative regulatory activity and stabilizes ErbB receptors. Lrig is a member of the Lrig family of transmembrane leucine-rich repeat proteins and is a negative regulator of several oncogenic receptor tyrosine kinases, including all members of the ErbB family [1,2,3], the Met [4] and Ret receptors [5]. We find that Lrig opposes Lrig negative action by enhancing ErbB receptor protein stability. Our data reveal a previously unappreciated complexity within the Lrig family

EXPERIMENTAL PROCEDURES
The abbreviations used are
RESULTS
DISCUSSION
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call